The changing healthcare landscape poses significant challenges to the traditional, segmented biopharmaceutical product development model. Asset development has become increasingly complex as companies trying to optimize their ROI work to meet the value objectives and evidence needs of different stakeholders in order to optimize the return on their assets. Addressing these needs in a non-integrated, linear way leads to decision-making biases, competing priorities, missed value-creation opportunities and adverse downstream.